The Right to Speak Out
By Editorial,
Nature
| 04. 09. 2013
What do Adam, Eve and the Queen of Sheba have to do with libel reform? Ask David Balding and Mark Thomas, geneticists at University College London (UCL) who received legal threats after they criticized the claims of a firm that sells people details of their genetic ancestry. Or ask the student journalists who feared a libel lawsuit if they covered the row in their university newspaper. Or the senate committee of the same university that was forced to slap down its own rector for actions contrary to academic freedom.
It is a messy and perhaps uniquely British farce, and one that highlights the desperate need to change English libel laws. And it shows why long-promised reform, due to be discussed again in Parliament later this month, might not go far enough.
The story began last July, when Balding and Thomas heard Alistair Moffat, chief executive of genetic-analysis company BritainsDNA and rector of the University of St Andrews, tell BBC radio that his firm had discovered Eve’s grandson and nine Britons directly descended from the Queen of Sheba. He added that...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...